IFNA1 and hepatitis C virus infection: In particular, the IFN-HSA chimeric protein (Albuferon, HGSI, Novartis) allows reducing the frequency of IFN therapy in the treatment of hepatitis C and supports dosing once every 2 or 4 weeks [26] thanks to improved pharmacokinetics, which is a significant improvement in therapy in comparison with therapy using free IFN or pegylated IFN [27].